BeOne Medicines Ltd
688235
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue.
Contact
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
stocks
After slump this ASX share may be an opportunity
Lower than expected guidance led to a sell-off.
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.40 | 53.80 | -0.59% |
| CAC 40 | 8,055.51 | 105.33 | 1.32% |
| DAX 40 | 23,959.99 | 390.03 | 1.65% |
| Dow JONES (US) | 47,368.63 | 381.53 | 0.81% |
| FTSE 100 | 9,787.15 | 104.58 | 1.08% |
| HKSE | 26,582.96 | 66.10 | -0.25% |
| NASDAQ | 23,527.17 | 522.64 | 2.27% |
| Nikkei 225 | 50,711.75 | 200.01 | -0.39% |
| NZX 50 Index | 13,604.55 | 12.93 | -0.09% |
| S&P 500 | 6,832.43 | 103.63 | 1.54% |
| S&P/ASX 200 | 8,818.80 | 56.80 | -0.64% |
| SSE Composite Index | 3,999.81 | 18.79 | -0.47% |